The emergence of chemotherapy as a survival-improving treatment for metastatic castration-resistant prostate cancer has focused attention on the need for effective prevention and management of side effects.
The most recent chemotherapeutic agent in this setting is cabazitaxel, licensed for use when the disease progresses on or after docetaxel-based treatment. Experience with cabazitaxel shows that, as with docetaxel, its side effects are largely predictable and manageable using methods that are already well-known to oncology teams. Patient education, clear instructions for when and how patients should seek advice, and properly implemented local policies on side effect management are essential to optimal patient care.
Written by:
Sperlich C, Saad F. Are you the author?
Hematologist-Oncologist and Professeur d'Enseignement Clinique, Clinique Intégrée de Cancérologie de la Montérégie (CICM), CSSS Charles-Le Moyne, Greenfield Park, QC
Reference: Can Urol Assoc J. 2013 Jan;7(2 Suppl 1):S18-24.
PubMed Abstract
PMID: 23682302
